Robeco Institutional Asset Management B.V. Has $2.32 Million Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Robeco Institutional Asset Management B.V. trimmed its stake in Laboratory Co. of America Holdings (NYSE:LH) by 19.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,379 shares of the medical research company’s stock after selling 2,539 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Laboratory Co. of America were worth $2,319,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of LH. Horizon Bancorp Inc. IN bought a new stake in Laboratory Co. of America in the third quarter worth approximately $29,000. Pathway Financial Advisers LLC bought a new stake in shares of Laboratory Co. of America in the 1st quarter valued at $30,000. Industrial Alliance Investment Management Inc. acquired a new position in shares of Laboratory Co. of America during the 2nd quarter valued at $27,000. Innealta Capital LLC bought a new position in Laboratory Co. of America during the second quarter worth $32,000. Finally, Riverview Trust Co grew its holdings in Laboratory Co. of America by 172.6% in the third quarter. Riverview Trust Co now owns 169 shares of the medical research company’s stock worth $38,000 after purchasing an additional 107 shares during the period. 95.94% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Kerrii B. Anderson sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the transaction, the director now owns 13,722 shares in the company, valued at approximately $3,156,060. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Glenn A. Eisenberg sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $223.99, for a total value of $3,359,850.00. Following the sale, the chief financial officer now owns 31,289 shares of the company’s stock, valued at $7,008,423.11. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kerrii B. Anderson sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $230.00, for a total transaction of $230,000.00. Following the completion of the transaction, the director now directly owns 13,722 shares of the company’s stock, valued at approximately $3,156,060. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,000 shares of company stock valued at $4,043,950. Company insiders own 0.85% of the company’s stock.

Laboratory Co. of America Trading Up 1.4 %

NYSE:LH opened at $242.39 on Friday. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $243.78. The firm has a 50-day moving average price of $223.02 and a two-hundred day moving average price of $214.30. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.30 and a current ratio of 1.44. The firm has a market cap of $20.27 billion, a price-to-earnings ratio of 46.88, a price-to-earnings-growth ratio of 1.93 and a beta of 1.05.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $3.50 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.02. The company had revenue of $3.28 billion during the quarter, compared to the consensus estimate of $3.26 billion. Laboratory Co. of America had a return on equity of 15.27% and a net margin of 3.43%. Laboratory Co. of America’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the business posted $3.38 earnings per share. On average, equities analysts expect that Laboratory Co. of America Holdings will post 14.53 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $2.88 dividend on an annualized basis and a yield of 1.19%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Analyst Ratings Changes

A number of research firms have recently issued reports on LH. Jefferies Financial Group increased their price objective on shares of Laboratory Co. of America from $245.00 to $265.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Bank of America raised their price objective on Laboratory Co. of America from $240.00 to $260.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Barclays upped their target price on Laboratory Co. of America from $234.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Friday, October 25th. Piper Sandler lifted their price target on shares of Laboratory Co. of America from $235.00 to $240.00 and gave the company a “neutral” rating in a research report on Monday, October 28th. Finally, HSBC upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Laboratory Co. of America currently has an average rating of “Moderate Buy” and a consensus target price of $255.92.

Laboratory Co. of America Company Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.